Y-Intercept (HK)
RAPP icon

Y-Intercept (HK)’s Rapport Therapeutics RAPP Stock Holding History

Y-Intercept (HK)’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-19,189
Closed -$800K – 2180
2026
Q2 		$800K Sell
19,189
-16,636
-46% -$611K 0.02% 1129
2026
Q1 		$1.12M Buy
+35,825
New +$1.01M 0.02% 985

Other funds holding RAPP

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Y-Intercept (HK)'s RAPP Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Rapport Therapeutics (RAPP) in Q3 2026, closing a stake of 19,189 shares — an estimated $800K sold.

Y-Intercept (HK) first reported a position in RAPP in Q1 2026 and held it in 2 quarters. The position peaked at $1.12M in Q1 2026. 54 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Rapport Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 19,189 Rapport Therapeutics shares in Q3 2026, an estimated $800K.
  • Y-Intercept (HK) first reported a position in Rapport Therapeutics in Q1 2026 and held it in 2 quarters.
  • Y-Intercept (HK)'s Rapport Therapeutics position peaked at $1.12M in Q1 2026.
  • 54 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.